Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System

Chimeric antigen receptor (CAR) T cell therapy has proven clinically beneficial against B cell acute lymphoblastic leukemia and non-Hodgkin’s lymphoma. However, suboptimal clinical outcomes have been associated with decreased expansion and persistence of adoptively transferred CAR T cells, antigen-n...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cell Rep
Glavni autori: Avanzi, Mauro P., Yeku, Oladapo, Li, Xinghuo, Wijewarnasuriya, Dinali P., van Leeuwen, Dayenne G., Cheung, Kenneth, Park, Hyebin, Purdon, Terence J., Daniyan, Anthony F., Spitzer, Matthew H., Brentjens, Renier J.
Format: Artigo
Jezik:Inglês
Izdano: 2018
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5986286/
https://ncbi.nlm.nih.gov/pubmed/29768210
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2018.04.051
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items